2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Drug Metabolite

Drug Metabolite

Drug Metabolite

Related Products

PDF 3.95 MB

Drug metabolite results when a drug is metabolized into a modified form which continues to produce effects. Drug metabolism redox reactions such as heteroatom dealkylations, hydroxylations, heteroatom oxygenations, reductions, and dehydrogenations can yield active metabolites, and in rare cases even conjugation reactions can yield an active metabolite.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-133787
    Levofloxacin N-oxide
    		98.28%
    Levofloxacin N-oxide is a minor metabolite of Levofloxacin (HY-B0330). Levofloxacin N-oxide does not exhibit significantly genotoxic risks. Levofloxacin is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria.
    Levofloxacin N-oxide
  • HY-W014225S
    3-Phenoxybenzoic acid-13C6
    		99.29%
    3-Phenoxybenzoic acid-13C6 is the 13C6 labeled 3-Phenoxybenzoic acid. 3-Phenoxybenzoic acid is the metabolite of pyrethroid insecticides. 3-Phenoxybenzoic acid induces immunotoxicity and oxidative stress, and inhibits the phagocytic ability of macrophages.
    3-Phenoxybenzoic acid-<sup>13</sup>C<sub>6</sub>
  • HY-100638
    RPR132595A
    RPR132595A (NPC) is an active metabolite of CPT-11, which is generated by cytochrome P-450 3A4 (CYP3A4) and finally excreted through urine.
    RPR132595A
  • HY-W394903
    GS-829845
    		99.91%
    GS-829845 is a major, active metabolite of Filgotinib (HY-18300). GS-829845 is a JAK1 preferential inhibitor but is approximately 10-fold less potent than the parent and with a longer half-life.
    GS-829845
  • HY-133794
    Dasatinib N-oxide
    		99.24%
    Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor.
    Dasatinib N-oxide
  • HY-131280
    Devaleryl Valsartan Impurity
    		99.99%
    Devaleryl Valsartan Impurity is an intermediate in the synthesis of Valsartan.
    Devaleryl Valsartan Impurity
  • HY-131579
    Deschloro Cetirizine dihydrochloride
    		99.44%
    Deschloro Cetirizine Dihydrochloride is a Cetirizine impurity. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist.
    Deschloro Cetirizine dihydrochloride
  • HY-W424779
    5-Carboxy-2′-deoxyuridine
    		98.98%
    5-Carboxy-2′-deoxyuridine is a metabolite of Trifluridine. 5-Carboxy-2′-deoxyuridine is a methyl oxidation product of Thymidine that can be formed by menadione-mediated photosensitization of Thymidine.
    5-Carboxy-2′-deoxyuridine
  • HY-113376
    Etiocholanolone glucuronide
    		≥98.0%
    Etiocholanolone glucuronide (Etio-G) is the metabolite of Etiocholanolone (HY-113320) that is generated in the liver by UDP glucuonyltransferase. Etiocholanolone glucuronide is promising for research of metabolic-related diseases.
    Etiocholanolone glucuronide
  • HY-N4173
    8-Oxoepiberberine
    		99.72%
    8-Oxoepiberberine is an alkaloid metabolite in the plasma after oral administration of Zuojin formula, a traditional chinese medicine used to treat gastrointestinal disease.
    8-Oxoepiberberine
  • HY-126857
    5-Hydroxyomeprazole
    5-Hydroxyomeprazole is the major metabolite of Omeprazole (HY-B0113).
    5-Hydroxyomeprazole
  • HY-G0014B
    Quetiapine sulfoxide hydrochloride
    Quetiapine sulfoxide hydrochloride (Quetiapine S-oxide hydrochloride) is a main metabolite of Quetiapinem. Quetiapine is a second-generation antipsychotic. Quetiapine is a 5-HT receptors agonist and a dopamine receptor antagonist.
    Quetiapine sulfoxide hydrochloride
  • HY-133779
    Gefitinib impurity 5
    		99.46%
    Gefitinib impurity 5 is the impurity of Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity.
    Gefitinib impurity 5
  • HY-W103882
    2-(Benzhydrylsulfinyl)acetic acid
    		99.57%
    2-Benzhydrylsulfinylacetic acid (Modafinil acid) is the metabolite of modafinil.
    2-(Benzhydrylsulfinyl)acetic acid
  • HY-13318S1
    Oseltamivir acid-13C,d3
    Oseltamivir acid-13C,d3 (GS 4071-13C,d3; Ro 64-0802-13C,d3) is a 13C- and deuterium-labeled Oseltamivir acid (HY-13318). Oseltamivir acid is the active metabolite of Oseltamivir phosphate and inhibits influenza virus neuraminidase (IC50=2 nM). Oseltamivir acid is orally active and can be used to study influenza A/B infections.
    Oseltamivir acid-<sup>13</sup>C,d<sub>3</sub>
  • HY-107856R
    5-Fluorouridine (Standard)
    5-Fluorouridine (Standard) is the analytical standard of 5-Fluorouridine. This product is intended for research and analytical applications. 5-Fluorouridine, a metabolite of 5-fluorouracil (HY-90006), is a potent ribozyme self-cleavage inhibitor. 5-Fluorouridine incorporates into both total and poly A RNA and has antiproliferative activity. 5-Fluorouridine induces apoptosis.
    5-Fluorouridine (Standard)
  • HY-109054
    O-Demethyltramadol
    O-Demethyltramadol is a primary active metabolite of Tramadol. O-Demethyltramadol is mainly responsible for its µ-opioid receptor-related analgesic effect. Tramadol is metabolized to O-Demethyltramadol mainly by the cytochrome P450 (CYP) 2D6 enzyme.
    O-Demethyltramadol
  • HY-G0001A
    Lurasidone Metabolite 14283 hydrochloride
    		99.06%
    Lurasidone Metabolite 14283 hydrochloride is a major active metabolite of Lurasidone. Lurasidone is a FDA approved agent for the treatment of schizophrenia.
    Lurasidone Metabolite 14283 hydrochloride
  • HY-156752
    Cyclosiversioside F 16,25-diacetate
    		99.68%
    Cyclosiversioside F 16,25-diacetate (Compound 6), a glycoside, is an alkaline hydrolysis product of Acetyl Derivative (Compound 2).
    Cyclosiversioside F 16,25-diacetate
  • HY-116016
    Etilevodopa
    		99.00%
    Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine.
    Etilevodopa
Cat. No. Product Name / Synonyms Application Reactivity